- Home
- FATE vs CVRX Comparison
FATE vs CVRX Comparison
Compare FATE & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | CVRX |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 139.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FATE | CVRX |
|---|---|---|
| Price | $2.80 | $2.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.10 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 2.4M | 208.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | $6,646,000.00 | ★ $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $0.91 | $4.37 |
| 52 Week High | $3.23 | $11.30 |
Technical Indicators
Market Signals| Indicator | FATE | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 62.56 |
| Support Level | $1.01 | $5.05 |
| Resistance Level | $3.22 | $5.96 |
| Average True Range (ATR) | 0.17 | 0.30 |
| MACD | -0.03 | 0.11 |
| Stochastic Oscillator | 37.50 | 95.59 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.